The Vilcek Foundation of New York City is looking for three foreign-born but U.S. resident scientists who have a PhD/MD or similar degree, the equivalent of an assistant professorship or higher in a research institution, and be either naturalized citizens or green card holders. They can be no older than 38 on New Year's Day 2014. The winning scientists must also be wizards at the bench and the publications keyboard.
The "Creative Promise in Biomedical Science" prizes are the creation of Ján Vilček, a professor at the NYU School of Medicine and philanthropist who developed the drug infliximab which, marketed as Remicade, is used to treat a string of autoimmune disorders including Crohn's disease. With his art historian wife, Marcia, Vilček came to New York in 1965 as a Cold War refugee and was grateful for a faculty spot at NYU. (Twenty years later, the Vilceks made NYU a $100 million gift of thanks.) His research with his NYU colleague Junming Le on monoclonals as TNF-α blocking agents led to the lucrative licensing of infliximab. The Vilceks formed their foundation in 2000, making awards both in the arts and biomedical science, including the $100,000 Vilcek Prizes in Biomedical Science for lifetime achievement by senior scientists who are U.S. immigrants.
Unlike the Vilcek senior prizes, which rely on closed nominating juries, the "Creative Promise" awards are self-nominations. The 2014 prize deadline is August 14 with announcement of the winners in November. Full details at www.vilcek.org.